Breaking News

Endo Appoints Corporate Development VP

April 29, 2014

Valeant veteran brings specialty pharma experience

Hemanth J. Varghese, Ph.D., CFA, has been appointed executive vice president of corporate development and strategy at Endo International. Dr. Robert Cobuzzi, who previously served in this role will now serve as senior vice president, U.S. branded pharmaceuticals R&D strategy and operations. Dr. Varghese will report to Rajiv De Silva, Endo's president and chief executive officer.
 
Dr. Varghese brings corporate development and general management experience in specialty pharmaceuticals, most recently serving as senior vice president and general manager vision care for Bausch & Lomb, a division of Valeant Pharmaceuticals. Dr. Varghese also held senior leadership roles at Valeant, including senior vice president of corporate development and general manager of Valeant's Neurology & Other business unit.
 
"We are excited to announce the addition of Hemanth to the Endo executive team. His accomplishments and experience in corporate development and integrations will allow us to accelerate the execution of our strategy as we continue to expand our business through value creating acquisitions and partnerships," said Mr. De Silva. "Hemanth's track record of success will play a significant role as we execute against our strategy to become a leading specialty healthcare company."

blog comments powered by Disqus
  • Cold Chain Packaging Trends

    Cold Chain Packaging Trends

    Kristin Brooks, Contract Pharma||February 4, 2016
    Susan Li of UPS discusses supply chain trends, challenges, and packaging innovations

  • Packaging Equipment Trends Preview

    Packaging Equipment Trends Preview

    Kristin Brooks, Contract Pharma||January 26, 2016
    Christian Treitel of Bosch Packaging Technology discusses trends and capabilities

  • Tackling Drug Serialization Challenges

    Tackling Drug Serialization Challenges

    Tim Wright, editor||January 22, 2016
    Siemens and Adents together will develop a combined hardware plus software solution for pharma industry

  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016